Autoimmune disease biotechnology company: Kyverna Therapeutics (KYTX)

Kyverna Therapeutics, Inc. (NASDAQ: KYTX) was founded in 2018, headquartered in Emeryville, California, USA, with 84 full-time employees. Kyverna Therapeutics is a cell therapy company, committed to developing new therapies for autoimmune diseases and inflammatory diseases.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kytx.html

Kyverna Therapeutics (KYTX)

Kyverna Therapeutics is a patient centered clinical company Biopharmaceutical Company , focusing on the development of cell therapy for patients with autoimmune diseases. Kyverna treatment platform combines advanced T cell engineering and synthetic biology technology, which can inhibit and eliminate the autoreactive immune cells in the root of autoimmune and inflammatory diseases. Kyverna's product line includes autologous and allogeneic next-generation chimeric antigen receptor T cells (CART) therapy, and its characteristics are very suitable for B-cell driven autoimmune diseases. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kytx.html

Kyverna's cell therapy methods for treating autoimmune diseases have been supported by scientific publications, including multiple autoimmune case studies using CD19 CAR T cells, as well as the early clinical data of the company's ongoing clinical trials, showing the disease modification potential of these therapies. This validation provides a clear path for Kyverna to continue to promote the clinical development of its main product candidate drug KYV-101 in two broad areas of autoimmune diseases: rheumatology and neurology. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kytx.html

Kyverna is the global exclusive licensor of the next generation CAR T construct targeting CD19, which is used for autologous (KYV-101) and allogeneic (KYV-201) cell therapy for B-cell driven autoimmune diseases. KYV-101 and KYV-201 have favorable properties applicable to autoimmunity. They combine the whole human anti-CD19 CAR with the costimulatory domain, aiming to minimize cytokine release, minimize B cells and improve clinical tolerance. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kytx.html

Kyverna Therapeutics intends to develop KYV-101 in two broad areas of autoimmune diseases: rheumatology and neurology. The company's initial development focus in rheumatology is lupus nephritis (LN) and systemic sclerosis (SSc). Kyverna is conducting two KYV-101 trials for patients with LN, which is an autoimmune disease. More than half of the patients cannot fully respond to the current treatment and are at risk of developing kidney failure. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kytx.html

In addition to LN, Kyverna Therapeutics obtained the IND license for Phase 1/2 research in SSC in October 2023. Kyverna initially focused its development in neurology on myasthenia gravis (MG) and multiple sclerosis (MS). Kyverna obtained the IND license for Phase 2 research in MG in November 2023, and obtained the IND license for Phase 2 research in MS in December 2023. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kytx.html

Kyverna Therapeutics (KYTX) US equity investment

On January 16, 2024, Phase II of cell therapy for autoimmune diseases Biotechnology Company Kyverna Therapeutics submitted to the SEC on Tuesday IPO It is proposed to raise up to US $100 million through IPO. Kyverna plans to be listed on NASDAQ with the stock code of KYTX. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kytx.html

On February 1, 2024, Kyverna Therapeutics announced that it planned to issue 11.1 million shares at a price of $17 to $19 to raise $200 million. At the midpoint of the proposed range, the fully diluted market value of Kyverna Therapeutics will reach $731 million. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kytx.html

On February 6, 2024, the latest plan of Kyverna Therapeutics is to issue 14.5 million shares at a price of $20 to $21, raising $297 million, 49% more than previously expected. J.P. Morgan 、 Morgan Stanley , Leerink Partners and Wells Fargo Securities co underwriting. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kytx.html

On February 8, 2024, Kyverna Therapeutics raised $319 million by issuing 14.5 million shares, and the issue price was $22, higher than the increased range of $20 to $21. JPMorgan Chase, Morgan Stanley, Leerink Partners and Wells Fargo bank Securities acted as the joint book keeper of this transaction. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/kytx.html

quotation	Direct market	transaction	Internal transaction
Encyclopedias	Encyclopedia of American Stocks	Shareholding	Ten institutions
Financial statements	Company financial report	option	Options Trading
Official website	Company official website	forecast	Revenue expectations